Pharmacovigilance (PV) is evolving beyond traditional spontaneous reporting. Patients contribute to safety monitoring through wearables, health apps, social media platforms, and mobile reporting tools.This shift is transforming how safety signals are identified, validated, and managed ,but it also introduces new risks for data accuracy, privacy, and audit readiness.
Patient-generated data offers real-time insights into drug safety and use, especially for chronic diseases and post-market monitoring. However, as the volume and variety of data increase, auditors face a new challenge: ensuring compliance and integrity in a landscape driven by technology and patient participation.
The Audit Challenge: Data That Doesn’t Fit the Old Model
Traditional PV audits focused on structured data ,clinical trials, call centres, regulatory submissions. Now, the data ecosystem includes:
- Wearables and connected devices capturing physiological data like heart rate, sleep, or glucose levels.
- Mobile health apps that track symptoms and side effects.
- Social media and online communities, where patients openly discuss their experiences with medicines.
While valuable, these data sources are unstructured, variable, and not always verifiable. This means PV auditors must assess systems, processes, and governance frameworks differently than before.
What Auditors Need to Look For
To ensure compliance and integrity in systems handling patient-generated data, auditors should focus on several key areas:
1. Data Governance and Traceability
Is there a clear framework defining how patient-generated data is collected, processed, and stored? Auditors should verify that data sources are traceable, authorised, and compliant with Good Pharmacovigilance Practice (GVP) and GDPR principles.
2. Validation of Digital Tools
Wearables, mobile apps, and reporting platforms must be validated for accuracy, reliability, and data security.Auditors should review validation reports, vendor oversight processes, and change control documentation.
3. Data Integrity and Quality Controls
Unstructured data must undergo quality checks before being used for safety assessment.Auditors should examine how organisations handle data cleaning, deduplication, and verification.
4. Consent and Privacy Compliance
Patients must know how their data will be used.Auditors must ensure informed consent procedures, privacy notices, and data anonymisation protocols are in place ,particularly when data originates from social platforms.
5. Integration with Core PV Systems
Auditors should assess how unconventional data feeds are integrated into the main PV system (e.g., safety databases, signal detection tools) and whether there are defined workflows for data triage, signal validation, and follow-up.
Why This Matters
Patient-generated safety data can greatly enhance pharmacovigilance by providing early signals and real-world insights.But without strong data governance, validation, and oversight, it can also introduce compliance and reputational risks.
Auditors play a crucial role in ensuring that as the PV landscape modernises, quality and compliance are not compromised.
How Q&V Supports the Future of Pharmacovigilance Auditing
At Q&V, we help organisations navigate the complexities of modern pharmacovigilance systems ,including those incorporating patient-generated data.
Our services include:
- PV system audits covering emerging data sources and digital reporting tools.
- Data governance and validation assessments for mobile and wearable technologies.
- GDPR and ethics compliance reviews to safeguard patient data.
- Training and readiness programmes for internal PV and QA teams.
As pharmacovigilance becomes increasingly data-driven, Q&V ensures that your systems remain compliant, ethical, and inspection-ready.
Stay Ahead with Q&V
Empower your pharmacovigilance system to handle the future of patient safety.
Contact Q&V to strengthen your audit processes and ensure compliance in the era of patient-generated data.